Login / Signup

Advances in prodrug design for Alzheimer's disease: the state of the art.

Valentin Travers-LesageSerge M MignaniPatrick DallemagneChristophe Rochais
Published in: Expert opinion on drug discovery (2022)
In the past 10 years, prodrugs have been approved by the FDA for the treatment of CNS pathologies. Most of them have been developed in order to improve membrane permeability of the parent drugs. Facing the limitation of AD drug discovery, the development of prodrugs will likely play a central role in the next years with the rise of innovative pleiotropic prodrugs.
Keyphrases
  • drug discovery
  • blood brain barrier
  • cognitive decline
  • endothelial cells
  • combination therapy
  • drug release
  • replacement therapy
  • mild cognitive impairment
  • smoking cessation